News
GTHX
3.860
-3.26%
-0.130
Weekly Report: what happened at GTHX last week (0415-0419)?
Weekly Report · 3d ago
G1 THERAPEUTICS TO RELEASE FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 1, 2024
Reuters · 04/17 13:00
Weekly Report: what happened at GTHX last week (0408-0412)?
Weekly Report · 04/15 09:21
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
5 analysts have released ratings for G1 Therapeutics (NASDAQ:GTHX) in the last three months. The company is a commercial-stage biopharmaceutical company developing drugs to treat cancer. The firm has an average 12-month price target of $10.8 and an average revenue growth rate of 45.1%. The company faces challenges in managing its debt.
Benzinga · 04/12 14:02
G1 Therapeutics Price Target Maintained With a $12.00/Share by Needham
Dow Jones · 04/12 10:11
Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal
Analyst Gil Blum of Needham maintained a Buy rating on G1 Therapeutics (GTHX) with a price target of $12.00. The positive outlook may hinge on the company’s innovative pipeline, strategic partnerships, and expected financial milestones. The company is developing small molecule therapeutics for the treatment of cancer.
TipRanks · 04/12 10:05
Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
Benzinga · 04/12 10:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. PetVivo Hldgs stock increased by 17.09% and SHL Telemedicine stock moved up by 13.26%. Losers include Supernus Pharmaceuticals and G1 Therapeutics.
Benzinga · 04/08 12:09
Weekly Report: what happened at GTHX last week (0401-0405)?
Weekly Report · 04/08 09:23
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) market cap touched US$250m last week, benefiting both retail investors who own 59% as well as institutions
G1 Therapeutics, Inc. (NASDAQ:GTHX) has a majority stake in the company with 35% of the stock. Retail investors own the lion's share of the company, with a total of 59% of shares. 25 investors have a majority of the shares in G1Therapeutics. The company is owned by the general public, but there are also institutional investors with a large stake. G1therapeutics is showing signs of insider selling and this could be a warning sign. It's worth looking at the different types of shareholders and their ownership of G1 TherAPEutics.
Simply Wall St · 04/07 12:48
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/01 20:20
Press Release: G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. Announced the grant of inducement stock options to one hired employee under the Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options are exercisable for 3,000 shares of G1's common stock and 1,500 restricted stock units. G1 is a commercial-stage oncology company.
Dow Jones · 04/01 20:20
Weekly Report: what happened at GTHX last week (0325-0329)?
Weekly Report · 04/01 09:22
Weekly Report: what happened at GTHX last week (0318-0322)?
Weekly Report · 03/25 09:23
G1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting Measures
G1 Therapeutics said its executive team will see their base salaries reduced by 10%. The company recently extended its cash runway into 2025. The pay cuts will be in place for a two-year period. The oncology company said the cuts will include temporary pay cuts for G1's executives.
Dow Jones · 03/22 22:35
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with lung cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer. Despite cash burn and dilution concerns, I rate GTHX a speculative "buy" for its promising product pipeline.
Seeking Alpha · 03/22 21:51
G1 Therapeutics Executives Take Pay Cut for Cost Management
TipRanks · 03/22 20:33
Weekly Report: what happened at GTHX last week (0311-0315)?
Weekly Report · 03/18 09:23
Market Sentiment Around Loss-Making G1 Therapeutics, Inc. (NASDAQ:GTHX)
G1 Therapeutics, Inc. Is a commercial-stage biopharmaceutical company. The company posted a loss of US$48m for its most recent financial year. G1Therapeutics is expected to grow 55% year-on-year to breakeven by 2026. Analyst's expect the company to be profitable in 2026, but the company has a high debt-to-equity ratio of 146%. The company is currently valued at US$163m by Simply Wall St.
Simply Wall St · 03/16 13:55
Weekly Report: what happened at GTHX last week (0304-0308)?
Weekly Report · 03/11 09:22
More
Webull provides a variety of real-time GTHX stock news. You can receive the latest news about G1 Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GTHX
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.